Stage IV Squamous Cell Lung Carcinoma AJCC v7 Active Not Recruiting Phase 2 / 3 Trials for Rilotumumab (DB11972)

IndicationStatusPhase
DBCOND0092102 (Stage IV Squamous Cell Lung Carcinoma AJCC v7)Active Not Recruiting2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02926638Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesTreatment